We wouldn’t be getting fast tracked with Keytruda
if there were issues with Efti. The fundamentals are better than anything on ASX in biotech(imo)
The problem is historical trading patterns, imo. It’s hard to shake the volatility once that becomes established.
Fundamentals are gradually getting the upper hand and support trend is steady. One good unexpected ann will blow the lid off it
News: IMM Immutep Granted Chinese Patent For Eftilagimod Alpha A In Combination With A PD-1 Pathway..., page-5
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |